Inhibrx Biosciences, Inc. INBX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Inhibrx Biosciences, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s EBITDA margin?
- Inhibrx Biosciences, Inc. (INBX) reported EBITDA margin of -10,195.5% in Q4 2025.
- How has Inhibrx Biosciences, Inc.'s EBITDA margin changed year-over-year?
- Inhibrx Biosciences, Inc.'s EBITDA margin increased by 93.8% year-over-year, from -164,582% to -10,195.5%.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s EBITDA margin?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s EBITDA margin has grown at a -8.3% compound annual growth rate (CAGR), from -12,112.8% to -10,195.5%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.